Femasys Inc. (FEMY)
1.05
0.00 (0.00%)
At close: Jan 14, 2025, 3:59 PM
1.05
0.00%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 1.03 |
| Market Cap | 24.04M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.81 |
| PE Ratio (ttm) | -1.3 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.1 |
| Volume | 58,659 |
| Avg. Volume (20D) | 186,563 |
| Open | 1.07 |
| Previous Close | 1.05 |
| Day's Range | 1.05 - 1.11 |
| 52-Week Range | 0.73 - 2.40 |
| Beta | undefined |
About FEMY
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United Sta...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Jun 18, 2021
Employees 32
Stock Exchange NASDAQ
Ticker Symbol FEMY
Website https://www.femasys.com
Analyst Forecast
According to 3 analyst ratings, the average rating for FEMY stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 852.38% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Femasys Inc. is scheduled to release its earnings on Mar 27, 2025,
during market hours.
Analysts project revenue of $1.47M, reflecting a 589.78% YoY growth and earnings per share of -0.18, making a -5.26% decrease YoY.
Analysts project revenue of $1.47M, reflecting a 589.78% YoY growth and earnings per share of -0.18, making a -5.26% decrease YoY.
4 months ago ·
Source
+7.48%
Femasys shares are trading higher after the compan...
Unlock content with
Pro Subscription
4 months ago ·
Source
+10.48%
Femasys shares are trading higher after the company announced CE Mark and Health Canada approved its FemVue MINI fallopian tube assessment solution
